Seleniso: Current status and future prospects of domestically produced drugs

Selinexor (Selinexor), a high-profile anti-tumor agent and nuclear export inhibitor, has already occupied a place in the domestic market. Although its original drug has obtained marketing approval in China and has been included in Class B medical insurance, no domestic pharmaceutical company has yet launched a domestic version of selinesol. However, what is worth looking forward to is that relevant research is being actively carried out in China. I believe that we will be able to see the launch of domestic Seleniso in the near future.

Selinesol has demonstrated significant therapeutic effects in the fields of multiple myeloma (MM) and diffuse large B-cell lymphoma (DLBCL). The combination of selinesol and dexamethasone provides a new treatment option for patients with relapsed or refractory multiple myeloma. This therapy is particularly useful for patients whose disease has become resistant to multiple medications after receiving multiple treatments. Similarly, the combination of selinesol with bortezomib and dexamethasone also provides an effective treatment for patients with multiple myeloma.

In the treatment of diffuse large B-cell lymphoma, selinesol has also demonstrated its unique advantages. Selinisol offers a new treatment option for patients who are relapsed or refractory after at least two systemic therapies. It is worth mentioning that the U.S. Food and Drug Administration (FDA) has designated selinesol as an orphan drug for the treatment of DLBCL, which further highlights its therapeutic potential in this field.

For domestic patients, the launch of selinesol will undoubtedly bring them more treatment opportunities. As the drug is included in the scope of Class B medical insurance, eligible patients can reimburse part of the cost through medical insurance, reducing their financial burden. Currently, the price of Seleniso on the domestic market is more than RMB 20,000 per box. The specific price may vary depending on region and market conditions. Patients in need can go to local hospitals or pharmacies to inquire about purchasing.